Startseite International Osteoporosis Foundation and International Federation of Clinical Chemistry and Laboratory Medicine Position on bone marker standards in osteoporosis
Artikel
Lizenziert
Nicht lizenziert Erfordert eine Authentifizierung

International Osteoporosis Foundation and International Federation of Clinical Chemistry and Laboratory Medicine Position on bone marker standards in osteoporosis

  • Samuel Vasikaran , Cyrus Cooper , Richard Eastell , Andrea Griesmacher , Howard A. Morris , Tommaso Trenti und John A. Kanis
Veröffentlicht/Copyright: 24. Mai 2011
Veröffentlichen auch Sie bei De Gruyter Brill

Abstract

The International Osteoporosis Foundation (IOF) and the International Federation of Clinical Chemistry and Laboratory Medicine (IFCC) Working Group on Bone Marker Standards (WG-BMS) has evaluated the clinical potential of bone turnover markers (BTMs) in the prediction of fracture risk and for monitoring treatment. Research evidence suggests that BTMs may provide information on fracture risk independently from BMD, so that fracture risk prediction might be enhanced by their inclusion in assessment algorithms. The potential use of BTMs to predict the response to treatments for osteoporosis in the individual patient is also of great interest. Treatment-induced changes in specific markers account for a substantial proportion of fracture risk reduction. However, there is still a need for stronger evidence on which to base practice in both situations. IOF/IFCC recommends one bone formation marker (serum procollagen type I N propeptide, s-PINP) and one bone resorption marker (serum C-terminal cross-linking telopeptide of type I collagen, s-CTX) to be used as reference markers and measured by standardised assays in observational and intervention studies in order to enlarge the international experience of the application of markers to clinical medicine and to help resolve uncertainties over their clinical use.


Corresponding author: Dr. Samuel Vasikaran, Core Clinical Pathology and Biochemistry Department, Royal Perth Hospital, Box X2213 GPO, Perth, WA 6847, Australia Phone: (+61) 8 9224 2453, Fax: (+61) 8 9224 1789

Received: 2011-03-25
Accepted: 2011-03-30
Published Online: 2011-05-24
Published in Print: 2011-08-01

©2011 by Walter de Gruyter Berlin Boston

Artikel in diesem Heft

  1. Editorial
  2. Pneumatic tube delivery systems for patient samples: evidence of quality and quality of evidence
  3. Reviews
  4. Translating pharmacogenetics into clinical practice: interleukin (IL)28B and inosine triphosphatase (ITPA) polymophisms in hepatitis C virus (HCV) infection
  5. New biomarkers for acute renal injury
  6. Minireview
  7. Post-mortem biochemistry of vitreous humor and glucose metabolism: an update
  8. Opinion Paper
  9. International Osteoporosis Foundation and International Federation of Clinical Chemistry and Laboratory Medicine Position on bone marker standards in osteoporosis
  10. Guidelines and Recommendations
  11. IFCC international conventional reference procedure for the measurement of free thyroxine in serum
  12. Genetics and Molecular Diagnostics
  13. Improving clinical laboratory efficiency: a time-motion evaluation of the Abbott m2000 RealTime and Roche COBAS AmpliPrep/COBAS TaqMan PCR systems for the simultaneous quantitation of HIV-1 RNA and HCV RNA
  14. Enhanced frequency of CFTR gene variants in couples who are candidates for assisted reproductive technology treatment
  15. Customer satisfaction survey to improve the European cystic fibrosis external quality assessment scheme
  16. General Clinical Chemistry and Laboratory Medicine
  17. Effect of sample collection, temperature and time of storage on β-galactosidase and total hexosaminidase activities in dried blood collected on filter paper
  18. Agreement between paired blood gas values in samples transported either by a pneumatic system or by human courier
  19. Golgi protein 73(GP73), a useful serum marker in liver diseases
  20. The utility of six over-the-counter (home) pregnancy tests
  21. N Latex FLC – new monoclonal high-performance assays for the determination of free light chain kappa and lambda
  22. Alterations of the preoperative coagulation profile in patients with acute appendicitis
  23. Cerebrospinal fluid findings in infants with pertussis or parapertussis1)
  24. Calcium pyrophosphate and monosodium urate crystals in synovial fluid as a cause of pseudoeosinophilia
  25. Cardiovascular Disease
  26. Dual activity of serum lipoprotein-associated phospholipase A2 yielding positive and inverse associations with cardiometabolic risk
  27. The value of N-terminal proB-type natriuretic peptide for early identification of myocardial infarction in patients with high-risk non-ST-elevation acute coronary syndromes
  28. Infectious Diseases
  29. Diagnosis and genotyping of Plasmodium falciparum by a DNA biosensor based on quartz crystal microbalance (QCM)
  30. Evaluation of two automated chemiluminescence immunoassays, the LIAISON Treponema Screen and the ARCHITECT Syphilis TP, and the Treponema pallidum particle agglutination test for laboratory diagnosis of syphilis
  31. Letters to the Editor
  32. The preanalytical influence of two different mechanical transport systems on laboratory analysis
  33. Commutability of the ERM-DA470k Reference Material for two assays measuring serum albumin using immunochemical principles
  34. Performance evaluation of the Vitros®3600 immunodiagnostic system for the determination of free thyroid hormones
  35. Towards laboratory knowledge, not data, in 70% of clinical decision-making. What “knowledge management” can add to clinical practice?
  36. How to obtain DNA from injection drug users?
Heruntergeladen am 11.10.2025 von https://www.degruyterbrill.com/document/doi/10.1515/CCLM.2011.602/html?lang=de
Button zum nach oben scrollen